<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - KETOROLAC TROMETAMOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>KETOROLAC TROMETAMOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term management of moderate to severe acute postoperative pain only</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 50 kg)</strong><br/>
                Initially 10 mg, then 10&#8211;30 mg every 4&#8211;6 hours as required for maximum duration of treatment 2 days, to be given over at least 15 seconds, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 60 mg per day.</li>
              <li class="dose adult"><strong>For adults (body-weight 50 kg and above)</strong><br/>
                Initially 10 mg, then 10&#8211;30 mg every 4&#8211;6 hours as required for maximum duration of treatment 2 days, to be given over at least 15 seconds, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 90 mg per day.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 10 mg, then 10&#8211;30 mg every 4&#8211;6 hours as required for maximum duration of treatment 2 days, to be given over at least 15 seconds, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 60 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Avoid unless the potential benefit outweighs the risk.</p><p>Avoid during the third trimester (risk of closure of fetal ductus arteriosus <i>in utero</i> and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p><p>Avoid in severe liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>The lowest effective dose should be used for the shortest possible duration.</p><p>Max. 60&#8239;mg daily by intramuscular injection or intravenous injection.</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Avoid if possible or use with caution.</p><p>Avoid if serum creatinine greater than 160&#8239;micromol/litre.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>rare:</strong> alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), hepatic damage, interstitial fibrosis associated with NSAIDs can lead to renal failure, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, pulmonary eosinophilia, Stevens-Johnson syndrome, toxic epidermal necrolysis, alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), hepatic damage, interstitial fibrosis associated with NSAIDs can lead to renal failure, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, pulmonary eosinophilia, Stevens-Johnson syndrome, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>notKnown:</strong> abnormal dreams, asthma, blood disorders, bradycardia, bronchospasm, chest pain, colitis (induction of or exacerbation of), confusion, convulsions, Crohn&#8217;s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, dry mouth, dyspnoea, euphoria, fluid retention (rarely precipitating congestive heart failure), flushing, gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, hallucinations, headache, hearing disturbances, hyperkalaemia, hyperkinesia, hypersensitivity reactions, hypertension, hyponatraemia, insomnia, malaise, myalgia, nausea, nervousness, pain at injection site, pallor, palpitation, paraesthesia, photosensitivity, psychosis, purpura, raised blood pressure, rashes, renal failure (especially in patients with pre-existing renal impairment), sweating, taste disturbances, thirst, tinnitus, urinary frequency, vertigo, visual disturbances, abnormal dreams, asthma, blood disorders, bradycardia, bronchospasm, chest pain, colitis (induction of or exacerbation of), confusion, convulsions, Crohn&#8217;s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, dry mouth, dyspnoea, euphoria, fluid retention (rarely precipitating congestive heart failure), flushing, gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, hallucinations, headache, hearing disturbances, hyperkalaemia, hyperkinesia, hypersensitivity reactions, hypertension, hyponatraemia, insomnia, malaise, myalgia, nausea, nervousness, pain at injection site, pallor, palpitation, paraesthesia, photosensitivity, psychosis, purpura, raised blood pressure, rashes, renal failure (especially in patients with pre-existing renal impairment), sweating, taste disturbances, thirst, tinnitus, urinary frequency, vertigo, visual disturbances, angioedema, optic neuritis,
              </p>
        
            <section class="advice">
                <h3>Serious side-effects</h3>
              <p>For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see <xref format="dita" href="#PHP78612" type="bookmark" namespace="/treatment-summaries/non-steroidal-anti-inflammatory-drugs">Non-steroidal anti-inflammatory drugs</xref>.</p>
            </section>
        
      </section>




      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">NSAIDs and cardiovascular events</p>
              <p>All NSAID use (including cyclo-oxygenase-2 selective inhibitors) can, to varying degrees, be associated with a small increased risk of thrombotic events (e.g. myocardial infarction and stroke) independent of baseline cardiovascular risk factors or duration of NSAID use; however, the greatest risk may be in those receiving high doses long term.</p><p>The lowest effective dose of NSAID should be prescribed for the shortest period of time to control symptoms and the need for long-term treatment should be reviewed periodically.</p>
            </section>
            <section class="importantSafetyInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">NSAIDs and gastro-intestinal events</p>
              <p>All NSAIDs are associated with serious gastro-intestinal toxicity; the risk is higher in the elderly. Evidence on the relative safety of non-selective NSAIDs indicates differences in the risks of serious upper gastro-intestinal side-effects&#8212;piroxicam, ketoprofen, and ketorolac are associated with the highest risk; indometacin, diclofenac, and naproxen are associated with intermediate risk, and ibuprofen with the lowest risk (although high doses of ibuprofen have been associated with intermediate risk). <b>Selective inhibitors of cyclo-oxygenase-2</b> are associated with a <i>lower risk</i> of serious upper gastro-intestinal side-effects than non-selective NSAIDs.</p><p>Recommendations are that NSAIDs associated with a low risk e.g. ibuprofen are <i>generally preferred</i>, to start at the <i>lowest recommended dose</i> and not to use more than one oral NSAID at a time.</p><p>The combination of a NSAID and low-dose aspirin can increase the risk of gastro-intestinal side-effects; this combination should be used only if absolutely necessary and the patient should be monitored closely.</p>
            </section>
            <section class="importantSafetyInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Asthma</p>
              <p>Any degree of worsening of asthma may be related to the ingestion of NSAIDs, either prescribed or (in the case of ibuprofen and others) purchased over the counter.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intramuscular use:</strong>
            allergic disorders
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            cardiac impairment (NSAIDs may impair renal function)
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            cerebrovascular disease
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            coagulation defects
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            connective-tissue disorders
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            Crohn&#8217;s disease (may be exacerbated)
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            elderly (risk of serious side-effects and fatalities)
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            heart failure
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            ischaemic heart disease
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            peripheral arterial disease
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            risk factors for cardiovascular events
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            ulcerative colitis (may be exacerbated)
          </li>
          <li>
              <strong>With intramuscular use:</strong>
            uncontrolled hypertension
          </li>
          <li>
              <strong>With intravenous use:</strong>
            allergic disorders
          </li>
          <li>
              <strong>With intravenous use:</strong>
            cardiac impairment (NSAIDs may impair renal function)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            cerebrovascular disease
          </li>
          <li>
              <strong>With intravenous use:</strong>
            coagulation defects
          </li>
          <li>
              <strong>With intravenous use:</strong>
            connective-tissue disorders
          </li>
          <li>
              <strong>With intravenous use:</strong>
            Crohn&#8217;s disease (may be exacerbated)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            elderly (risk of serious side-effects and fatalities)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            heart failure
          </li>
          <li>
              <strong>With intravenous use:</strong>
            ischaemic heart disease
          </li>
          <li>
              <strong>With intravenous use:</strong>
            peripheral arterial disease
          </li>
          <li>
              <strong>With intravenous use:</strong>
            risk factors for cardiovascular events
          </li>
          <li>
              <strong>With intravenous use:</strong>
            ulcerative colitis (may be exacerbated)
          </li>
          <li>
              <strong>With intravenous use:</strong>
            uncontrolled hypertension
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use</h3>
              <p>Caution&#8212;long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.</p>
            </section>
      </section>











      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID&#8212;which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of KETOROLAC TROMETAMOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77512"><a href="../medicinalForm/PHP77512.html" data-target="#PHP77512" data-action="load">Solution for injection</a></div>
            <div id="PHP77508"><a href="../medicinalForm/PHP77508.html" data-target="#PHP77508" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
